Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ANI PharmaceuticalsANIP -5.35%80 EV-to-EBITDA is 9.23 as of Aug. 08, 2026, which is 38% below its 10-year median of 14.97. GuruFocus rates ANIP with a GF Score™ of 80/100 and a GF Value™ of $101.57 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 739 Drug Manufacturers companies, ANI Pharmaceuticals ranks better than 63.46% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, ANI Pharmaceuticals's enterprise value is $2,066.7 Mil.
ANI Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $223.8 Mil. Therefore, ANI Pharmaceuticals's EV-to-EBITDA for today is 9.23.
The historical rank and industry rank for ANI Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
ANIP'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -185.45 Med: 14.97 Max: 277.8
Current: 9.23
During the past 13 years, the highest EV-to-EBITDA of ANI Pharmaceuticals was 277.80. The lowest was -185.45. And the median was 14.97.
ANIP's EV-to-EBITDA is ranked better than 63.46% of 739
companies
in the Drug Manufacturers industry
Industry Median: 13.37
vs ANIP: 9.23
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
ANI Pharmaceuticals (NAS:ANIP) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
ANI Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
ANI Pharmaceuticals's share price for today is $78.45.
ANI Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.950.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for ANI Pharmaceuticals's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, ANI Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ANI Pharmaceuticals EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ANI Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where ANI Pharmaceuticals's EV-to-EBITDA falls into.
ANI Pharmaceuticals's current Enterprise Value is $2,066.7 Mil.
ANI Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $223.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ANI Pharmaceuticals (ANIP) has a EV-to-EBITDA of 9.23 as of Aug. 08, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on ANI Pharmaceuticals. This is 38% below median its historical median of 14.97. According to the industry distribution chart, ANI Pharmaceuticals ranks #270 out of 739 companies in the Drug Manufacturers industry, placing it in the top 36.5%.
Is ANI Pharmaceuticals' EV-to-EBITDA too high?
ANI Pharmaceuticals' current EV-to-EBITDA of 9.23 is 38% below median its 10-year median of 14.97. The Drug Manufacturers industry median EV-to-EBITDA is 13.37. ANI Pharmaceuticals' value of 9.23 is 31% below this industry median. Based on the distribution chart, ANI Pharmaceuticals ranks #270 out of 739 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, ANI Pharmaceuticals has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ANI Pharmaceuticals' EV-to-EBITDA compare to TRLV and AMLX?
According to the Drug Manufacturers industry distribution chart, ANI Pharmaceuticals ranks #270 out of 739 companies for EV-to-EBITDA. This puts ANI Pharmaceuticals in the upper half of its industry. The industry median EV-to-EBITDA is 13.37. ANI Pharmaceuticals' value of 9.23 is 31% below this benchmark. While the company's 10-year median is 14.97 vs. the industry median of 13.37, ANI Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.37, based on 739 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ANI Pharmaceuticals's current EV-to-EBITDA of 9.23 is 31% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on ANI Pharmaceuticals. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ANI Pharmaceuticals's current EV-to-EBITDA is 9.23, which is 38% below median its own 10-year median of 14.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ANI Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ANI Pharmaceuticals (ANIP) is currently considered Modestly Undervalued. The stock's GF Value™ is $101.57, compared to a current price of $78.45 — trading 22.8% below its estimated fair value. The current EV-to-EBITDA is 9.23, which is 38% below median its 10-year median of 14.97 and 31% below the Drug Manufacturers industry median of 13.37. ANI Pharmaceuticals' overall GF Score™ is 80/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For ANI Pharmaceuticals (ANIP), the current EV-to-EBITDA is 9.23 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ANI Pharmaceuticals (ANIP) Overvalued in 2026?
Based on GuruFocus' analysis, ANI Pharmaceuticals stock appears to be undervalued.
The current stock price of $78.45 is trading 22.8% below its estimated GF Value™ of $101.57.
GuruFocus considers ANI Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for ANIP:
EV-to-EBITDA: 9.23 (38% below median its 10-year median of 14.97)
GF Value™: $101.57 vs. price of $78.45 (22.8% below fair value)
Industry Position: 31% below the Drug Manufacturers median (#270 of 739)
No single metric tells the full story. See the ANIP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.
80GF Score
Get the complete analysis for ANIP
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ANIP has been successfully added to your 
